Therapeutics case studies

Learn more on how we bring life changing therapies to market.

Providing empirically based guidance and built-to-spec models and solutions across every phase of clinical research and lifecycle management for therapeutic development.

Triple negative breast cancer

A large, multinational pharmaceutical company needed to better understand patient perspectives to optimize protocol and study design and operationalise a study for TNBC.

Successes in phase 2 autologous cellular therapy Oncology programme

ICON was awarded two early development cancer immunotherapy studies from a biotherapeutic company for a potentially ground¬breaking autologous cellular therapy in the treatment of two tumour types.

Study in type 1 diabetes patients

Sponsor proposed a randomized, open-label, multi-centre, parallel-group study comparing the safety and efficacy of STUDY DRUG with Novolog in type 1 diabetes (T1D) patients.

Severe COPD phase III case study

A sponsor conducting an international Phase III program of two double-blind, randomised studies consulted ICON’s respiratory experts for assistance in patient enrolment, and study planning and monitoring.

Complex, early-phase study in Huntington’s disease

ICON was contracted to conduct an early-phase clinical trial in Huntington’s disease across 12 countries and 53 sites.

Long-term follow-up study for rare disease gene therapy

ICON provided full-service support to a large biotech company in two global Phase 3 trials for a gene therapy product treating spinal muscular atrophy (SMA), a rare but serious condition causing muscle wasting and weakness.

Trial decentralisation

Clinical trial participation exposes rare disease participants to significant pressure financially, logistically and psychologically, and these incremental pressures can negatively impact a patient’s ability or willingness to enrol or remain in a clinical trial.

Rapid mobilisation to advance COVID-19 treatment development

In February 2020 ICON quickly mobilised its vaccine and infectious disease resources to assist government
and commercial clients in addressing the COVID-19 global threat.

Pivotal study in TBI

There are no specific pharmaceutical therapies available for TBI. Since 2001, ICON staff have participated in managing mult national TBI trials with several drugs including endopeptidase inhibitor and endothelin converting enzyme inhibitors, involving more than 1,000 TBI patients.